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The vast majority of glomangiomas are small, benign neoplasms that can occur anywhere
in the body but typically arise in the subcutaneous tissues of the extremities and are
capable of causing extreme pain. Typically, these lesions are managed surgically with
excellent rates of tumor control. On occasion, patients present with a variant of the
glomangioma tumor consisting of numerous or recurrent nodules, a condition classified
as glomangiomatosis. The authors present a case report of a young patient with multiply
recurrent painful glomangiomas of the left foot, who was ultimately diagnosed with
glomangiomatosis pedis. After multiple surgeries and surgical consultations, no surgery
other than amputation was recommended. Therefore, the patient sought consultation with
regard to stereotactic body radiation therapy (SBRT). In the absence of other options, and
based on its effectiveness in treating glomus tumors of the head and neck which display
similar natural history and histologic features, SBRT was offered. The patient underwent
SBRT to the largest of his remaining tumors with excellent local control and significant
reduction in pain at two and a half years follow-up.
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INTRODUCTION
Peripheral glomus tumors which most often present subungually
in the digits of the upper extremities are primarily small, clin-
ically benign neoplasms of the dermis and hypodermis (Folpe
et al., 2001). They typically present with a classic triad of pain out
of proportion to examination, temperature sensitivity, and point
tenderness, though these symptoms are non-specific and not nec-
essary for diagnosis. These lesions were better characterized by
Masson in 1924 as arising from the glomus body, a neuromyoarte-
rial apparatus responsible for thermoregulation (Masson, 1924).
It has since been found that glomus tumors constitute less than
1% of all neoplasms of the soft tissue and usually occur in the
extremities or sometimes in the jugular foramen (glomus jugu-
lare) as singular nodules (Looi et al., 1999). Some patients may be
afflicted with multiple glomus tumors, a condition known as glo-
mangiomatosis. As a subset of glomus tumors, patients afflicted
with glomangiomatosis tend to present with multiply recurrent
peripheral tumors (Moor et al., 1999).
Herein, we describe the use of stereotactic body radiation ther-
apy (SBRT) with anecdotal experience from the treatment of
glomus jugulare in the therapy of a young patient with multiple
and recurrent glomangiomas of the left foot.
CASE PRESENTATION
A 28 year-old Caucasian male without otherwise notable past
medical history presented with a 13 year history of pain sec-
ondary to multiple tumors of the left foot. He underwent his
first surgical excision at the age of 17 after 2 years of progres-
sively worsening discomfort. Pathologically determined to be a
glomangioma, this lesion was removed from the posteriolat-
eral ankle soft tissues. An additional lesion was resected 2 years
later from the anterolateral heel. The patient underwent four
additional surgeries at 2, 3, 4, and 6 years following initial pre-
sentation and was ultimately diagnosed with glomangiomatosis
pedis. He had been referred for further surgery including pos-
sible amputation, which he declined. He initiated care with our
institution ∼6 years following the last surgery (12 years fol-
lowing initial presentation). His symptoms included increasing
swelling and pain of his largest lesion over the lateral tarsal
region of his left foot. The pain was described as consistent
at 2 out of 10 in intensity, with regular exacerbations to 9/10
(Houde, 1982). Examination revealed an approximate 2 cm pal-
pable tumor over the lateral aspect of the left foot at the level of the
calcaneocuboid articulation. The patient experienced exquisite
tenderness over the region of the sinus tarsi which correlated
with a remaining surgical clip on radiographic examination.
He had mild diminution in sensation near his surgical scars,
but motor function remained intact. Computed tomography
(CT)/Magnetic resonance imaging (MRI) revealed multiple soft
tissue masses throughout the left mid and hindfoot, with the
largest mass located in the lateral hindfoot and measuring 1.8 cm
in greatest dimension, having grown from 1.37 cm 8 months
prior and correlating to the location of his current symptoms
(Figure 1).
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Histologic evaluation from the most recent surgical excision
(6 years prior to presentation to our service) consisted of mul-
tiple samples, all consistent with glomangiomatosis (Figure 2).
Microscopically, they were a collection of fibroconnective and
fibromuscular soft tissues which appeared as focal limited vascu-
lar proliferation with increased perivascular cellularity.
As part of this patient’s work-up, he was referred to three sep-
arate surgeons specializing in Podiatric, Plastic, and Orthopedic
surgeries. The patient declined superficial peroneal nerve resec-
tion to remove the retained surgical clip. He was otherwise ruled
inappropriate for further surgical intervention with the exception
of amputation. With this, the patient was offered SBRT for local
control of the largest and currently troublesome lesion. He was
not offered therapy for the remainder of his lesions at the time
of presentation for a number of reasons. As this modality had
not been utilized for the treatment of a glomangioma of the foot,
the results and consequences of SBRT to the hindfoot were rel-
atively uncertain and our primary goal was to do no harm. We
were concerned about the outcomes of offering additional treat-
ment on the patient’s multiply resected and resultantly fibrotic
foot. Further, the remaining lesions were asymptomatic and the
course of their progression was uncertain. If his remaining lesions
were to progress and additional radiotherapy deemed necessary,
there were concerns over cumulative dose to the bones of the
foot and related pathological fractures as a late toxicity as well as
increasing the level of fibrosis already present from prior surgical
interventions.
He was counseled as to the relative dearth of literature regard-
ing the use of this modality in the treatment of peripheral glomus
tumors. The patient elected to proceed with SBRT for treatment
of his symptomatic lesion.
IRRADIATION TECHNIQUE
Treatment was delivered using the CyberKnife robotic SBRT sys-
tem (Multiplan version 2.1.0, Accuray, Inc.) with 6-MV photons
from a linear accelerator mounted on a fully articulated robotic
arm. Due to the difficulty of implanting fiducials in the foot,
five golden fiducials were affixed to the patient’s foot at the time
of CT simulation and tattoos were used to mark their positions
(Figure 3). The fiducials were affixed to his foot over the tat-
toos at the time of obtaining the MRI for treatment planning
and for each treatment session to monitor intrafraction tumor
FIGURE 1 | (A) Sagittal T1 weighted image demonstrates a 1.8cm
T1 isointense round mass in the lateral subcutaneous soft tissues,
plantar to the peroneal tendons. (B) The lesion is hyperintense on
T2 fat suppressed images. (C) The lesion demonstrates a small
area of central contrast enhancement on T1 fat suppressed images
(whereas it demonstrated homogenous enhancement on earlier
studies). A smaller lesion is partially seen posterior to the dominant
lesion.
FIGURE 2 | Representative section from the left foot mass shows vascular tumor containing perivascular proliferation of small cuboidal epithelioid
cells without atypia around open vascular spaces (HandE stains, A, 40×; B, 200×).
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motion with orthogonal kV x-rays. Treatment was administered
to the patient as an outpatient in five fractions over the course of
7 days. His lesion was treated on consecutive days, starting on a
Wednesday and ending on a Tuesday, excluding the weekend. His
foot was immobilized using a TriVac SecureVac Cushion (Bionix
Development Corp.). Because of the tumor’s location, the treat-
ment was planned utilizing fused CT and MRI scans. The gross
tumor volume (GTV) was outlined on each scan and on CT was
4.6 cm3 and on MRI was 3.2 cm3. The CT-GTV and MRI-GTV
were fused with rigid registration and expanded by 5mm to cre-
ate the clinical tumor volume (CTV). The CTV was expanded
by 2mm to create the planning tumor volume (PTV) (Figure 4).
The PTV was prescribed to 30Gy in 6Gy fractions to the 71%
isodose line. Inverse planning was used to determine the dose
to the target volume while minimizing the dose to normal tis-
sue. Dose constraints to the talus were adapted from the 22Gy
threshold dose for ribs found in Benedict et al.’s (2010) guide-
lines for tissue constraints (Benedict et al., 2010). For the talus,
a larger bone, a slightly higher threshold of 25Gy was utilized.
The minimum and maximum doses to the CT-GTV were 31.2
and 41.4Gy, respectively. For the MRI-GTV, the minimum and
maximum doses were 32.9 and 42.3Gy, respectively. Each GTV
received 100% of the prescribed dose. The talus was also out-
lined to quantitate the dose delivered, which was a maximum of
2260 cGy.
FOLLOW-UP
The patient tolerated therapy with no significant complications
and only mild soreness over his instep which resolved shortly fol-
lowing completion of treatment. He followed up with our clinic at
regular 6-month intervals, includingMRI imaging of his left foot.
His MRI at 6 months post-treatment showed no new lesions as
well as a decrease in size of the target lesion to 1.1 cm in maximal
dimension, a reduction of 0.7 cm (Figure 5). At 6 and 12 month
follow-up, he noted a resolution of his baseline discomfort with
significantly less severe exacerbations with a maximum of 4 out of
10 (9/10 prior to treatment). At 2.5 years of follow-up, the patient
continued to endorse reduced pain at the site of the treated lesion.
He did, however, complain of recent onset of new pains similar
to those of the past on the dorsal surface of the left foot near
the proximal diaphysis of the fourth-metatarsal. These pains were
accompanied by the ability to palpate a nodule in the region of
FIGURE 3 | (A) Lateral view of immobilization device. Small strips of tape hold gold fiducials over placeholder tattoo markings. (B) Medial view of
immobilization device with two placeholder tattoos. (C) Lateral view of immobilization device with three placeholder tattoos.
FIGURE 4 | The CyberKnife treatment plan utilizing-fused CT and MRI
scans of the left foot. The gross tumor volume was outlined on both
scans and prescribed a dose of 3000 cGy. Thin orange is the CT-GTV,
which was treated to a minimum of 3122cGy and a maximum of
4139cGy. Thin red represents the MRI-GTV, which was treated to a
minimum of 3289cGy and a maximum of 4225cGy. Each GTV received
100% of the prescribed dose. The two GTVs were fused with an
extension of 2mm to create the CTV (thick orange) and a margin of 5mm
was added (thick purple) was added to create the PTV. The talus was
outlined and kept to a maximum of 2260cGy.
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the pain. This is consistent with the most recent imaging, which
showed an increase in size to 0.9 cm of an existing nodule seen
on previous studies (Figure 6). Treatment of the new lesion was
delayed at the patient’s wishes.
DISCUSSION
In 2001, Folpe et al. proposed a classification scheme for glomus
tumors with the following categories: malignant glomus tumor,
glomus tumor of uncertain malignant potential, symplastic glo-
mus tumor, and glomangiomatosis (Folpe et al., 2001). Under
this new system, glomus tumors were differentiated from glo-
mangiomas by their histological similarity to angiomas (Folpe
et al., 2001). In contrast to solitary glomus tumors, glomangiomas
more closely resemble venous malformations than the glomus
body (Schopp et al., 2009). Additionally, the natural history of
the glomangioma is also distinct from the glomus tumor. Again
in contrast to those with solitary glomus tumors, patients with
glomangiomatosis tend to present at a younger age and with
peripheral tumors that are rarely subungual (Moor et al., 1999).
There has also been evidence to suggest that there is a famil-
ial component to glomangiomatosis, with patients inheriting the
trait in an autosomal dominant fashion (Shotton et al., 1987).
For most glomus tumors, embolization followed by surgical
excision remains the first-line intervention (Schopp et al., 2009).
Stereotactic radiosurgery and SBRT have also been used to treat
solitary, residual, and recurrent glomus jugulare tumors with
good results (Lim et al., 2007; Wegner et al., 2010; Guss et al.,
2011; Ivan et al., 2011; Sheehan et al., 2012). An extensive liter-
ature search revealed only one documentation of external beam
radiation therapy being utilized to treat multiple peripheral glo-
mus tumors (Nishimoto et al., 1990). To our knowledge, SBRT
has not been reported in the management of glomus tumors or
their variants in the extremities, making our use of the technique
for the treatment of glomangiomatosis unique.
The incidence of glomangiomatosis is estimated to be 2 in
1,000,000 and one-third of these cases will present before the
patients are 20 years old (Goodman and Abele, 1971; Duggan
et al., 2008). Glomangiomas can present in any location, such
as the extremities, trachea, lungs, nasal cavity, stomach, kid-
neys, and others (Al-Ahmadie et al., 2007; Alempijevic et al.,
2008; McKenna and Kerr, 2008; Miyamoto and Wada, 2009;
Parker et al., 2010; Rao et al., 2010; Santambrogio et al.,
2011). Though glomangiomas have the potential to present any-
where in the body, they most often present in the extremities
FIGURE 5 | (A) Sagittal T1 weighted image obtained 6 months following the patient’s SBRT treatment demonstrates interval decrease in the size of the dominant
mass to 1.1cm. (B) It remains hyperintense on T2FS images. (C) It also demonstrates homogeneous enhancement on T1 fat suppressed post contrast images.
FIGURE 6 | (A) Sagittal T1 weighted image obtained ∼2 years following the
patient’s SBRT treatment demonstrates interval development of an enlarging
T1 isointense nodule within the subcutaneous soft tissues dorsal to the
fourth-metatarsal diaphysis. (B) It is hyperintense on T2 fat suppressed
images. (C) Similar to previously identified masses, it demonstrates contrast
enhancement on T1 fat suppressed post contrast imaging.
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(Anakwenze et al., 2008; Glazebrook et al., 2010). Because this
condition is rare but often debilitating due to the pain of the
tumors, surgical treatment is usually necessary for problematic
lesions. In cases of glomangiomatosis, this can lead to disfig-
urement from multiple procedures on a small area and may
ultimately lead to amputation of a digit or limb. In an effort to
avoid this outcome, radiation therapy has been investigated as an
alternative treatment modality.
Focused radiation therapy has been shown to at least control,
if not resolve symptoms resulting from glomus tumors, espe-
cially the glomus jugulare (Nishimoto et al., 1990; Lim et al.,
2007; Wegner et al., 2010; Guss et al., 2011; Ivan et al., 2011;
Sheehan et al., 2012). In choosing an appropriate treatment dose,
two factors were considered: the success of previously reported
treatment schemes and the possibility of late toxicity from treat-
ment. Two series from the University of Pittsburgh and Stanford
University utilizing SBRT for the treatment of glomus jugulare
tumors reported excellent outcomes using 16–25 Gy in 1–5 fx and
14–27 Gy in 2 or 3 fx (Lim et al., 2007; Wegner et al., 2010). In two
series from Princess Margaret Hospital related to the treatment of
lower extremity soft tissue sarcoma with conventionally fraction-
ated external beam radiation, pathological fracture rates were as
high as 10% in patients treated to greater than 60Gy and risk of
fracture was elevated when the mean dose to the bone was greater
than 37Gy or maximum point dose was greater than 59 Gy (Holt
et al., 2005; Dickie et al., 2009). Further, the Bendict et al.’s 2010
guidelines were taken into account, ensuring maximum point
doses to bony structures were less than 30Gy (Benedict et al.,
2010).
Given that the patient was being treated to a relatively small
area adjacent to the talus and the possibility of the patient requir-
ing future SBRT to other progressing tumors, we chose to treat
only the dominant lesion to a dose of 30 Gy. Following treatment
to the dominant lesion, the patient was able to return to running
regularly without pain or discomfort. This is not only a testament
to the success of the treatment, but also to the fact that the other
lesions, while present, were asymptomatic. In the event that the
patient does require further SBRT to the left foot in the future, he
will certainly be at an increased risk of pathological fracture with
increased cumulative dose to the bones of the hindfoot. The local
control was excellent as not only did the progression of his most
problematic lesion halt as would have been expected based on the
glomus jugulare literature, but it reduced in size by 0.7 cm with-
out any side effects other than a short-lived tenderness in his foot.
Patients with multiply recurrent glomangiomas of the extremity,
SBRT may provide a limb sparing alternative with excellent local
control and minimal toxicity. Due to the small sample size and
retrospective nature of the report, this technique warrants fur-
ther investigation to delineate the role of SBRT in the treatment
of glomangiomas.
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